Thomas R Blue, Michael S Gordon, Frank J Vocci, Marc J Fishman, Shannon Gwin Mitchell, Kevin Wenzel
{"title":"A Naturalistic Study of Individuals Involved in the Justice System Who Experienced Both Formulations of Extended-release Buprenorphine.","authors":"Thomas R Blue, Michael S Gordon, Frank J Vocci, Marc J Fishman, Shannon Gwin Mitchell, Kevin Wenzel","doi":"10.1097/ADM.0000000000001430","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to compare participants' experiences on two different formulations of extended-release buprenorphine.</p><p><strong>Methods: </strong>Participants were part of a larger parent study comparing Brixadi™ (extended-release buprenorphine), hereafter called Brixadi, to extended-release naltrexone. At the time, Brixadi, was not fully FDA approved, and because of medication supply issues, 12 individuals were switched to Sublocade™ (a different formulation of extended-release buprenorphine), hereafter called Sublocade, for one dose and then back to Brixadi. Ten of those individuals completed semistructured interviews regarding their experiences with each medication.</p><p><strong>Results: </strong>In general, most participants preferred Brixadi, and most found Sublocade to cause more injection site pain/discomfort. Participants' experiences with respect to cravings, medication wearing off too soon, withdrawal symptoms, and perceived helpfulness with recovery are also discussed.</p><p><strong>Conclusions: </strong>Patients may prefer Brixadi to Sublocade because of injection site pain/discomfort. This could be mitigated with topical or subcutaneous anesthetics. Findings are mixed with respect to the effect of the medications on cravings, withdrawal symptoms, and the medication wearing off too soon. To address feelings of the medication wearing off too soon, patients could be given additional weekly doses of Brixadi (for patients on monthly doses of Brixadi) or supplemental sublingual buprenorphine (for patients on either Brixadi or Sublocade).</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Addiction Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ADM.0000000000001430","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: This study aimed to compare participants' experiences on two different formulations of extended-release buprenorphine.
Methods: Participants were part of a larger parent study comparing Brixadi™ (extended-release buprenorphine), hereafter called Brixadi, to extended-release naltrexone. At the time, Brixadi, was not fully FDA approved, and because of medication supply issues, 12 individuals were switched to Sublocade™ (a different formulation of extended-release buprenorphine), hereafter called Sublocade, for one dose and then back to Brixadi. Ten of those individuals completed semistructured interviews regarding their experiences with each medication.
Results: In general, most participants preferred Brixadi, and most found Sublocade to cause more injection site pain/discomfort. Participants' experiences with respect to cravings, medication wearing off too soon, withdrawal symptoms, and perceived helpfulness with recovery are also discussed.
Conclusions: Patients may prefer Brixadi to Sublocade because of injection site pain/discomfort. This could be mitigated with topical or subcutaneous anesthetics. Findings are mixed with respect to the effect of the medications on cravings, withdrawal symptoms, and the medication wearing off too soon. To address feelings of the medication wearing off too soon, patients could be given additional weekly doses of Brixadi (for patients on monthly doses of Brixadi) or supplemental sublingual buprenorphine (for patients on either Brixadi or Sublocade).
期刊介绍：
The mission of Journal of Addiction Medicine, the official peer-reviewed journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical sub-specialty.
Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics including:
•addiction and substance use in pregnancy
•adolescent addiction and at-risk use
•the drug-exposed neonate
•pharmacology
•all psychoactive substances relevant to addiction, including alcohol, nicotine, caffeine, marijuana, opioids, stimulants and other prescription and illicit substances
•diagnosis
•neuroimaging techniques
•treatment of special populations
•treatment, early intervention and prevention of alcohol and drug use disorders
•methodological issues in addiction research
•pain and addiction, prescription drug use disorder
•co-occurring addiction, medical and psychiatric disorders
•pathological gambling disorder, sexual and other behavioral addictions
•pathophysiology of addiction
•behavioral and pharmacological treatments
•issues in graduate medical education
•recovery
•health services delivery
•ethical, legal and liability issues in addiction medicine practice
•drug testing
•self- and mutual-help.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
